Want to see CELU full AI Analyst Report?
CELU Stock Chart & Stats
$0.80
-$0.01(-1.32%)
At close: 4:00 PM EDT
$0.80
-$0.01(-1.32%)
Day’s Range― - ―
52-Week Range$0.56 - $2.55
Previous Close$2.13
Volume48.12K
Average Volume (3M)8.20M
Market Cap
$38.21M
Enterprise Value$116.37
Total Cash (Recent Filing)$6.17M
Total Debt (Recent Filing)$40.90M
Price to Earnings (P/E)―
Beta3.34
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.69
Shares Outstanding28,945,961
10 Day Avg. Volume150,402
30 Day Avg. Volume8,196,274
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.75
Price to Sales (P/S)1.07
P/FCF Ratio-2.14
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$44.00M
Bulls Say, Bears Say
Bulls Say
Placental-derived Allogeneic Therapy PlatformCelularity’s focus on allogeneic, off-the-shelf therapies gives it a platform-oriented development model across oncology and regenerative medicine. Its placental sourcing and processing capabilities support multiple cell and biomaterial programs, creating potential for recurring licensing, collaboration, and product opportunities.
Improving Cash-burn TrajectoryAlthough Celularity remains cash-flow negative, the reduction in free-cash-flow outflows indicates progress toward better spending discipline and operating efficiency. If maintained, lower cash consumption could extend funding capacity and reduce the pace at which external capital is needed to support development.
Leadership ConsolidationThe expanded roles for two executives described as central to recent financing, restructuring, and strategic initiatives may improve continuity and decision-making. Concentrating operational, legal, and strategic responsibilities could support more consistent execution as Celularity manages financing and regulatory complexity.
Bears Say
Revenue Contraction And Persistent LossesRecent revenue deterioration alongside continuing operating and net losses shows that Celularity has not yet established a scalable commercial model. Persistent unprofitability limits internally generated funding, increases dependence on financing or partnerships, and makes future investment in its pipeline more difficult.
Negative Equity And Elevated LeverageNegative equity materially weakens Celularity’s financial cushion and reduces flexibility in allocating capital. With debt remaining substantial relative to its capital base, the company faces greater refinancing and dilution risk, which could constrain development spending and weaken its negotiating position with financiers.
Continued Dependence On External CapitalCelularity continues to consume cash rather than fund operations internally, leaving clinical development and corporate activities reliant on financing, collaborations, or other capital sources. Combined with weakened equity, this dependence can make funding less predictable and increase dilution or refinancing pressure.
Celularity News
CELU FAQ
What was Celularity’s price range in the past 12 months?
Celularity lowest stock price was $0.56 and its highest was $2.55 in the past 12 months.
What is Celularity’s market cap?
Celularity’s market cap is $38.21M.
When is Celularity’s upcoming earnings report date?
Celularity’s upcoming earnings report date is Apr 01, 2027 which is in 187 days.
How were Celularity’s earnings last quarter?
Celularity released its earnings results on Aug 18, 2025. The company reported -$1.02 earnings per share for the quarter, missing the consensus estimate of -$0.75 by -$0.27.
Is Celularity overvalued?
According to Wall Street analysts Celularity’s price is currently Overvalued.
Does Celularity pay dividends?
Celularity does not currently pay dividends.
What is Celularity’s EPS estimate?
Celularity’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Celularity have?
Celularity has 28,945,961 shares outstanding.
What happened to Celularity’s price movement after its last earnings report?
Celularity reported an EPS of -$1.02 in its last earnings report, missing expectations of -$0.75. Following the earnings report the stock price went down -0.826%.
Which hedge fund is a major shareholder of Celularity?
Currently, no hedge funds are holding shares in CELU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Celularity Stock Smart Score
Company Description
Celularity
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
Technical Analysis
Ownership Overview
14.57% Insiders
2.63% Mutual Funds
3.05% Other Institutional Investors
77.60% Public Companies and
Individual Investors